Recommendations of the CADTH for Treating Chronic Viral Hepatitis Genotypes 2 to 4 with Direct-Acting Agents

Description

Current therapy of chronic viral hepatitis C is highly dynamic, with multiple regimens involving direct-acting agents (DAA). Therapeutic regimens vary based on viral genotype and disease severity. Therapy is best directed by a physician who are experienced in treating viral hepatitis.

Patient selection: chronic hepatitis C virus, genotype 2, 3 or 4

Direct-acting agents (DAA) include:

(1) sofosbuvir (SOF)

(2) daclatasvir (DCV)

Parameters:

(1) genotype

(2) "experience" with pegylated interferon (PI) plus ribavirin (RBV) therapy (treatment naive)

(3) cirrhosis

Genotype	Previous Rx	Cirrhosis	Regimen
2	NA	NA	SOF + RBV for 12 weeks
3	NA	No	SOF + DCV for 12 weeks
3	NA	Yes	SOF + RBV for 24 weeks
4	No	No	SOF + RBV + PI for 12 weeks
4	No	Yes	insufficient evidence
4	Yes	NA	insufficient evidence

To read more or access our algorithms and calculators, please log in or register.

Recommendations of the CADTH for Treating Chronic Viral Hepatitis Genotypes 2 to 4 with Direct-Acting Agents

Description

Specialty